Pemigatinib (Pemazyre)

Ingredients: Pemigatinib
Dosage Form: Oral tablets
Innovator’s Brand Name: Pemazyre
Generic Brand Name: Peminib
Generic Manufacturer: Ziska Pharma

Indications:
Pemigatinib is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma whose tumors harbor fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements confirmed by an FDA‑approved test.

Dosage and Administration:
The recommended dose is 13.5 mg orally once daily, administered in 21‑day cycles (e.g., 14 days on treatment followed by 7 days off). Dose and schedule may be adjusted based on clinical response and tolerability.

Adverse Reactions:
Common adverse reactions include hyperphosphatemia, alopecia, stomatitis, diarrhea, fatigue, nausea, and dry mouth.

Storage:
Store in a cool, dry place below 30 °C, protected from light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link